154 related articles for article (PubMed ID: 38806761)
1. Important Predictive Factors for the Prognosis of Patients With Peritoneal Metastasis of Gastric Cancer.
Torun BC; Sobutay E; Akbulut OE; Saglam S; Yilmaz S; Yonemura Y; Canbay E
Ann Surg Oncol; 2024 May; ():. PubMed ID: 38806761
[TBL] [Abstract][Full Text] [Related]
2. Surgery with hyperthermic intraperitoneal chemotherapy after response to induction chemotherapy in patients with peritoneal metastasis of gastric cancer.
Canbay E; Canbay Torun B; Cosarcan K; Altunal C; Gurbuz B; Bilgic C; Sezgin C; Kaban KK; Yilmaz S; Yazici Z
J Gastrointest Oncol; 2021 Apr; 12(Suppl 1):S47-S56. PubMed ID: 33968425
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
4. Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study).
Bonnot PE; Lintis A; Mercier F; Benzerdjeb N; Passot G; Pocard M; Meunier B; Bereder JM; Abboud K; Marchal F; Quenet F; Goere D; Msika S; Arvieux C; Pirro N; Wernert R; Rat P; Gagnière J; Lefevre JH; Courvoisier T; Kianmanesh R; Vaudoyer D; Rivoire M; Meeus P; Villeneuve L; Piessen G; Glehen O;
Br J Surg; 2021 Oct; 108(10):1225-1235. PubMed ID: 34498666
[TBL] [Abstract][Full Text] [Related]
5. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal hyperthermic chemotherapy after cytoreduction in patients with peritoneal metastases from endometrial cancer. The next frontier?
Navarro-Barrios Á; Gil-Martínez J; Ramos-Bernardo I; Barrios P; Muñoz-Casares C; Torres-Melero J; Pereira F; Manzanedo I; Arjona Á; Martínez-Regueira F; Cascales-Campos PA
Surg Oncol; 2020 Jun; 33():19-23. PubMed ID: 32561085
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
Yu P; Ye Z; Dai G; Zhang Y; Huang L; Du Y; Cheng X
BMC Cancer; 2020 Nov; 20(1):1108. PubMed ID: 33198674
[TBL] [Abstract][Full Text] [Related]
8. Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases.
Ihemelandu C; Mavros MN; Sugarbaker P
Ann Surg Oncol; 2016 Dec; 23(13):4231-4237. PubMed ID: 27338748
[TBL] [Abstract][Full Text] [Related]
9. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.
Chang SC; Fingerhut A; Chen WT
Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126
[TBL] [Abstract][Full Text] [Related]
10. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
[No Abstract] [Full Text] [Related]
11. Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study.
van der Kaaij RT; Braam HJ; Boot H; Los M; Cats A; Grootscholten C; Schellens JH; Aalbers AG; Huitema AD; Knibbe CA; Boerma D; Wiezer MJ; van Ramshorst B; van Sandick JW
JMIR Res Protoc; 2017 Jul; 6(7):e136. PubMed ID: 28705789
[TBL] [Abstract][Full Text] [Related]
12. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases.
Steinhoff H; Acs M; Blaj S; Dank M; Herold M; Herold Z; Herzberg J; Sanchez-Velazquez P; Strate T; Szasz AM; Piso P
World J Gastroenterol; 2023 May; 29(18):2850-2863. PubMed ID: 37274066
[TBL] [Abstract][Full Text] [Related]
13. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.
Canbay E; Mizumoto A; Ichinose M; Ishibashi H; Sako S; Hirano M; Takao N; Yonemura Y
Ann Surg Oncol; 2014 Apr; 21(4):1147-52. PubMed ID: 24356799
[TBL] [Abstract][Full Text] [Related]
14. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
[TBL] [Abstract][Full Text] [Related]
15. Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Kuijpers AM; Mehta AM; Boot H; van Leerdam ME; Hauptmann M; Aalbers AG; Verwaal VJ
Ann Oncol; 2014 Apr; 25(4):864-869. PubMed ID: 24667719
[TBL] [Abstract][Full Text] [Related]
16. HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits?
Hotopp T
Surg Oncol; 2019 Mar; 28():159-166. PubMed ID: 30851894
[TBL] [Abstract][Full Text] [Related]
17. Conversion Surgery for Patients with Advanced Gastric Cancer with Peritoneal Carcinomatosis.
Lee TY; Liao GS; Fan HL; Hsieh CB; Chen TW; Chan DC
J Oncol; 2021; 2021():5459432. PubMed ID: 34804160
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy Followed by Cytoreductive Surgery and HIPEC Improves Survival in Peritoneal Metastatic Gastric Cancer.
Akturk Esen S; Ozgun YM; Hasturk D; Ucar G; Bostanci EB; Sendur MAN; Uncu D
Oncology; 2023; 101(5):321-327. PubMed ID: 36809752
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis.
Rau B; Brandl A; Thuss-Patience P; Bergner F; Raue W; Arnold A; Horst D; Pratschke J; Biebl M
Gastric Cancer; 2019 Nov; 22(6):1226-1237. PubMed ID: 31065877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
